specificity for the CD20 molecule for potential use in adoptive immunotherapy of B-cell malignancies. We show that cTCR þ
CD8
þ NKT cells can be expanded in large quantities and are highly effective in lysing CD20 molecule expressing Daudi and Raji tumor cell lines, as well as freshly isolated malignant B lymphocytes from B-CLL patients. In competitive targeting studies, we were able to dissect the major pathways of tumor cell recognition and found that endowing CD8 þ NKT cells with CD20z chimeric receptors resulted in a significant increase of cytotoxic activity against CD20
þ Daudi targets as compared to nontransduced effectors.
We also demonstrate that chimeric receptor mediated cytotoxicity is dependent on the expression level of the target antigen. Tumor targets expressing high levels of CD20 molecule (Daudi) were lysed more efficiently than low level expressing targets (Raji). Of importance, cytotoxicity of ex vivo expanded cTCR þ CD8 þ NKT cells was more potent as compared to ex vivo expanded cTCR þ CD8 þ T cells. We believe these differences in cytotoxic activity to be a result of cultured CD8 þ T cells being sensitized for activation induced cell death (AICD) following repetitive stimulation with IL-2. In addition, functional cTCR signaling was documented by detection of high levels of the Th-1 cytokine IFN-g secreted by cTCR þ CD8 þ NKT cells upon CD20 antigen target recognition. Of interest, blocking the adhesion molecules LFA-1/ICAM-1 had no major influence on chimeric T-cell receptor mediated cytotoxicity of CD8 þ NKT cells. Our results suggest that cellular immunotherapy using human ex vivo expanded CD8 þ NKT cells expressing CD20 antigenspecific cTCR could add to standard treatment regimens for CD20 þ B-cell malignancies, for example to overcome recurrent or refractory disease, with the advantage of minor additional toxicity. However, further studies are needed to determine the optimal use of genetically engineered cTCR þ CD8 þ NKT cells. Finally, the proposed immunotherapeutic strategy may also be applicable to other neoplastic diseases by modification of the candidate gene. Multiple myeloma (MM) is a hematological malignancy characterized by accumulation in the bone marrow of plasma cells that secrete a monoclonal immunoglobulin (Ig). The implication of natural killer cells (NK) in antitumor immunity against MM is suggested by plasmocyte susceptibility to NK lysis.
1 NK efficiently kill early-stage MM cells by a natural cytotoxicity receptor (NCR)-and NKG2D-dependent pathway. 2 In contrast, late-stage MM cells are protected from NK lysis by a high expression of HLA class I molecules. 2 In addition to this immune evasion mechanism involving the target cell, 2 we tested the hypothesis of an additional mechanism involving the effector cell, that is, NK, as previously described in leukemic patients. 3 We analyzed peripheral NK from six MM patients at diagnosis. The activating receptor expression was checked on CD19 À CD3 À CD56 þ cells by flow cytometry using mAbs against NKp30, NKp44, NKp46, NKG2D, CD16 and 2B4/CD244 (for patient descriptions, see Supplementary Information).
In MM patients, the percentage of NKp30-expressing NK (69%718) and the mean fluorescence intensity (MFI ¼ 42731) did not statistically differ (P ¼ 0.28, Mann-Whitney non-parametric test; Figure 1 ) from 23 healthy donors (86%711 positive cells, MFI ¼ 56737). In MM patients, the percentage of NKp46-expressing NK (80%715) and the MFI (62735) did not statistically differ (P ¼ 0.18) from healthy donors (85%78 positive cells, MFI ¼ 86758). In MM patients, we did not detect NKp44 expression on resting NK, as the expression of this receptor is restricted to activated NK. 4 All NK from MM patients or healthy donors expressed NKG2D. The MFI of NKG2D was lower in MM patients than in healthy donors, but the difference did not reach statistical difference (65735 vs 83713, P ¼ 0.13). The 2B4/CD244 receptor was expressed on all NK, both in MM and healthy donors. Nonetheless, 2B4/CD244 MFI in MM patient NK was drastically lower than in healthy donors (129761 vs 3047119, P ¼ 0.001). NK from MM patients all expressed CD16, but the MFI was reduced in MM patients compared to healthy donors NK (117765 vs 2307123, P ¼ 0.021). As an invariant control, no significant differences were observed regarding the expression of CD56 on NK in healthy donors vs MM patients.
We conclude to a normal expression of NCR and NKG2D in MM patients, in agreement with data from Carbone et al. Nonetheless, the coreceptor 2B4/CD244 and the low-affinity IgFc receptor CD16 displayed significantly weaker expression in comparison with healthy donors. Continuous exposure to the circulating monoclonal Ig may explain CD16 downmodulation. This downregulation might more specifically impair the antibody-dependent cytotoxicity. We have demonstrated that MM plasmocytes express CD48, the ligand for 2B4/CD244 (shown in Supplementary Information). As a consequence of 2B4/CD244 downregulation, NK might lack the NCR costimulation provided by CD48-expressing plasmocytes. Defective CD48-2B4/CD244 interaction is a novel mechanism that may further favor, in addition to the upregulation of HLA class I, escape of MM plasmocytes to innate immunity. 
